BRCA WT Ovarian Gradalis is targeting a Phase 3 registration trial in ovarian cancer focused on BRCA WT patients, following positive signals in Phase 2b. This subpopulation presents a clear co development or licensing opportunity for partners seeking to accelerate a competitive ovarian cancer program and leverage biomarker driven patient selection.

Platform Synergy Vigil's bi-shRNA platform employs three mechanisms to enhance anti-tumor immunity, including reducing immunosuppression by blocking furin, boosting effector cells via GM-CSF, and presenting full tumor neo-antigens, supported by Phase 2b signals and all comers in Phase 1 activity. Potential for partnerships around combination regimens with PD-1/PD-L1 inhibitors or other immunotherapies across solid tumors.

Academic Partnerships Gradalis has demonstrated collaboration with academia, notably a project with McMaster University, and possesses a pipeline including extracellular matrix technology for tumor cell expansion. This opens doors for licensing or co development deals to access manufacturing platforms, cell expansion capabilities, or biomarker tools.

Financial Scale Readiness With modest revenue in the lower tens of millions and existing funding, Gradalis may be open to milestone driven or co development financing to advance late stage trials and bring Vigil toward commercialization, reducing single company financial burden and enabling rapid scale.

Clinical Market Momentum A leadership change with a new CEO in 2026 and ongoing Phase 3 planning signals a forward looking growth trajectory. This is attractive for strategic partners seeking a late stage clinical immunotherapy with a differentiated mechanism and potential for high value global access in solid tumors.